<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hypertensive Heart Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Hypertensive Heart Disease</span>
        </nav>

        <header class="page-header">
            <h1>Hypertensive Heart Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Cardiovascular</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0001302" target="_blank">
                        MONDO:0001302
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Hypertension</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Heart Disease</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">18</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cardiovascular disorder</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Left Ventricular Hypertrophy
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Thickening of the heart&#39;s main pumping chamber (left ventricle) in response to high blood pressure.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16097361" target="_blank">PMID:16097361</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are the early manifestations of cardiovascular target organ damage in patients with arterial hypertension and signify hypertensive heart disease."</div>
                
                
                <div class="evidence-explanation">The reference indicates that left ventricular hypertrophy (LVH) is a manifestation of hypertensive heart disease, but it does not explicitly state that LVH is a subtype of hypertensive heart disease. However, since it implies a direct relationship, partial support is inferred.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Coronary Artery Disease
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Narrowing of the blood vessels that supply the heart, worsened by hypertension.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37739329" target="_blank">PMID:37739329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque,..."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions the contribution of hypertension to the development of coronary artery disease, which involves narrowing of the blood vessels that supply the heart.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Heart Failure
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Weakening of the heart muscle, leading to reduced pumping efficiency, often as a result of long-standing hypertension.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31472888" target="_blank">PMID:31472888</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertensive heart disease represents a spectrum of illnesses from uncontrolled hypertension to heart failure."</div>
                
                
                <div class="evidence-explanation">The abstract indicates that heart failure can develop as part of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36030347" target="_blank">PMID:36030347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the..."</div>
                
                
                <div class="evidence-explanation">The study supports the presence of heart failure as an outcome of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35679365" target="_blank">PMID:35679365</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Several factors chronically lead to HF, including cardiac volume and pressure overload that may result from hypertension."</div>
                
                
                <div class="evidence-explanation">Heart failure as a result of hypertension is explicitly mentioned.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Increased Cardiac Workload</div>
                
                <div class="item-desc">Hypertension increases the pressure the heart must pump against, leading to cardiac remodeling and dysfunction over time.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38428029" target="_blank">PMID:38428029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathologic cardiac hypertrophy is a common consequence of many cardiovascular diseases, including aortic stenosis (AS). AS is known to increase the pressure load of the left ventricle, causing a compensative response of the cardiac muscle, which progressively will lead to dilation and heart failure."</div>
                
                
                <div class="evidence-explanation">This reference discusses the pressure load on the left ventricle due to aortic stenosis, leading to cardiac remodeling and dysfunction, supporting the described mechanism of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7496052" target="_blank">PMID:7496052</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension is associated with the remodeling of left ventricular geometry and abnormalities of function that may precede geometric changes. Rather than a specific disease, &#39;hypertensive heart failure&#39; is a spectrum of disorders that result from left ventricular geometric changes and comorbid..."</div>
                
                
                <div class="evidence-explanation">The reference explains the remodeling of the left ventricle due to hypertension and the functional abnormalities that occur, supporting the described mechanism of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19427497" target="_blank">PMID:19427497</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"LVDD as an early measure of myocardial end-organ damage is commonly associated with hypertension and may well precede development of LVH in hypertension."</div>
                
                
                <div class="evidence-explanation">This reference discusses the association between hypertension and left ventricular dysfunction, an early indicator of cardiac remodeling and dysfunction, supporting the described mechanism.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Left Ventricular Hypertrophy</div>
                
                <div class="item-desc">The heart muscle thickens to cope with increased workload, but this can lead to stiffness and impaired filling.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11062603" target="_blank">PMID:11062603</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Sustained increase in arterial pressure causes left ventricular hypertrophy and adversely affects all myocardial compartments: myocytes, interstitium, and coronary vasculature."</div>
                
                
                <div class="evidence-explanation">The paper discusses how hypertension causes left ventricular hypertrophy and affects multiple myocardial compartments.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36933415" target="_blank">PMID:36933415</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We computed both eccentric and concentric hypertrophy effects and tracked changes in the ventricle shape and wall thickness."</div>
                
                
                <div class="evidence-explanation">The study confirms that changes in wall thickness and ventricular shape due to hypertrophy reflect an adaptation to increased workload.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10652906" target="_blank">PMID:10652906</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular hypertrophy (LVH) is pathognomonic of HHD."</div>
                
                
                <div class="evidence-explanation">Left ventricular hypertrophy is directly associated with hypertensive heart disease and involves thickening of the heart muscle.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Myocardial Ischemia</div>
                
                <div class="item-desc">Hypertension can worsen atherosclerosis in the coronary arteries, reducing blood flow to the heart muscle.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37739329" target="_blank">PMID:37739329</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque,..."</div>
                
                
                <div class="evidence-explanation">This reference outlines how hypertension can lead to coronary artery disease by affecting atherosclerotic plaque development, endothelial dysfunction, and coronary circulation, which are consistent with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11062603" target="_blank">PMID:11062603</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Sustained increase in arterial pressure causes left ventricular hypertrophy and adversely affects all myocardial compartments: myocytes, interstitium, and coronary vasculature. Ventricular hypertrophy significantly increases the risk for cardiovascular morbidity and mortality in hypertensive..."</div>
                
                
                <div class="evidence-explanation">The report discusses the negative impact of hypertension on coronary circulation and the involvement of coronary vasculature impairments due to hypertensive disease, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33143256" target="_blank">PMID:33143256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ischemic heart disease still represents a large burden on individuals and health care resources worldwide. By conventions, it is equated with atherosclerotic plaque due to flow-limiting obstruction in large-medium sized coronary arteries. However, clinical, angiographic and autoptic findings..."</div>
                
                
                <div class="evidence-explanation">This reference explains that ischemic heart disease, which can result from severe atherosclerotic plaques, aligns with the statement that hypertension-induced atherosclerosis can reduce coronary blood flow, contributing to myocardial ischemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cardiac Fibrosis</div>
                
                <div class="item-desc">Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it. TGF-Œ≤/SMAD signaling drives fibroblast-to-myofibroblast transition and increased collagen deposition.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cardiac Fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002548" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        collagen fibril organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030199" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        myocardial interstitium
                        
                    </span>
                    
                    <span class="tag tag-location">
                        perivascular space
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37999643" target="_blank">PMID:37999643</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In response to increased peripheral resistance in hypertension, intensified mechanical stretch in the myocardium induces cardiomyocyte hypertrophy and fibroblast activation to withstand increased pressure overload. This changes the structure and function of the heart, leading to pathological..."</div>
                
                
                <div class="evidence-explanation">The activation of fibroblasts in response to hypertension and their role in cardiac remodeling aligns with the statement that chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33568808" target="_blank">PMID:33568808</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Diffuse myocardial fibrosis resulting from the excessive deposition of collagen fibres through the entire myocardium is encountered in a number of chronic cardiac diseases. This lesion results from alterations in the regulation of fibrillary collagen turnover by fibroblasts, facilitating the..."</div>
                
                
                <div class="evidence-explanation">This reference details how fibroblasts facilitate excessive collagen deposition in the myocardium, which supports the statement regarding cardiac fibrosis due to chronic pressure overload.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2532916" target="_blank">PMID:2532916</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In left ventricular pressure overload a reactive interstitial fibrosis, having distinctive biochemical and structural features, is seen. This reactive fibrosis occurs in the absence of myocyte necrosis, is progressive in nature, and initially is an adaptive response that preserves the force..."</div>
                
                
                <div class="evidence-explanation">The description of reactive interstitial fibrosis in response to pressure overload supports the statement about fibroblasts depositing excess collagen in the heart under chronic pressure overload conditions, leading to fibrosis and stiffening.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Coronary Microvascular Dysfunction</div>
                
                <div class="item-desc">Hypertension causes endothelial dysfunction, microvascular rarefaction, and perivascular fibrosis in the coronary microvasculature, reducing coronary flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes to ischemia and progression to heart failure with preserved ejection fraction.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        pericyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000669" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        angiogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001525" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        regulation of nitric oxide biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0045428" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        coronary microvasculature
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress and Mitochondrial Dysfunction</div>
                
                <div class="item-desc">NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in response to mechanical stress and Ang II signaling. This oxidative stress damages mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways including NF-Œ∫B.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        superoxide metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006801" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        mitochondrial electron transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006123" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Inflammasome Activation</div>
                
                <div class="item-desc">Pressure overload and oxidative stress activate the NLRP3 inflammasome, leading to caspase-1 activation and release of IL-1Œ≤ and IL-18. This inflammatory signaling amplifies cardiac fibrosis, hypertrophy, and adverse remodeling.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammasome complex assembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0061702" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        interleukin-1 beta production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0032611" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Dyspnea[&#34;Dyspnea&#34;]
    Reduced_Exercise_Tolerance[&#34;Reduced Exercise Tolerance&#34;]
    Arrhythmias[&#34;Arrhythmias&#34;]
    Palpitations[&#34;Palpitations&#34;]
    Syncope[&#34;Syncope&#34;]
    Heart_Failure_Exacerbations[&#34;Heart Failure Exacerbations&#34;]

    Dyspnea --&gt; Reduced_Exercise_Tolerance
    Dyspnea --&gt; Heart_Failure_Exacerbations
    Arrhythmias --&gt; Palpitations
    Arrhythmias --&gt; Syncope
    Arrhythmias --&gt; Palpitations
    Arrhythmias --&gt; Syncope

    style Dyspnea fill:#fef3c7
    style Reduced_Exercise_Tolerance fill:#fef3c7
    style Arrhythmias fill:#fef3c7
    style Palpitations fill:#fef3c7
    style Syncope fill:#fef3c7
    style Heart_Failure_Exacerbations fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">18</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(9)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Genitourinary<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Respiratory<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Constitutional<span class="pill-count">(6)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">9</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arrhythmias
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Palpitations</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Syncope</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34809918" target="_blank">PMID:34809918</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PH due to LHD is associated with negative impact on outcomes in addition to worse symptoms and exercise capacity."</div>
                
                
                <div class="evidence-explanation">While this supports the cardiovascular phenotype in the context of arrhythmias, it does not specifically mention palpitations or syncope as sequelae of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36202538" target="_blank">PMID:36202538</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Evaluation of cardiac phenotypes in secondary hypertension provides a unique opportunity to study underlying hormonal and biochemical mechanisms affecting the heart."</div>
                
                
                <div class="evidence-explanation">This implies a variety of cardiac phenotypes can be seen in hypertension but does not explicitly list arrhythmias, palpitations, or syncope.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arrhythmias
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Arrhythmias like atrial fibrillation are more common in hypertensive heart disease</div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Palpitations</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Syncope</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31472889" target="_blank">PMID:31472889</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertensive heart disease can manifest as cardiac arrhythmias. Supraventricular and ventricular arrhythmias may occur in the hypertensive patients."</div>
                
                
                <div class="evidence-explanation">The literature supports that hypertensive heart disease can manifest as arrhythmias, but it does not specifically address the frequency as &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36519436" target="_blank">PMID:36519436</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension is prevalent in &gt;70% of atrial fibrillation patients. In turn, hypertensive patients have up to 73% greater likelihood of atrial fibrillation."</div>
                
                
                <div class="evidence-explanation">The literature supports the association between hypertension and atrial fibrillation but does not specify the frequency of arrhythmias in hypertensive heart disease as &#39;occasional&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Aortic Dissection
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002647" target="_blank">
                                Aortic dissection
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002647)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hypertension is a major risk factor for aortic dissection</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11419663" target="_blank">PMID:11419663</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Essential treatment includes rapid initiation of pharmacologic agents to control hypertension."</div>
                
                
                <div class="evidence-explanation">This reference indicates that controlling hypertension is essential in the treatment of aortic dissection, supporting the notion that hypertension is a major risk factor for aortic dissection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25620633" target="_blank">PMID:25620633</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In this review, we discuss cardiovascular hypertensive emergencies, including acute coronary syndrome, aortic dissection, congestive heart failure, and sympathomimetic hypertensive crises."</div>
                
                
                <div class="evidence-explanation">This reference discusses aortic dissection as a cardiovascular hypertensive emergency, supporting the statement that hypertension is a major risk factor for aortic dissection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25573747" target="_blank">PMID:25573747</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A clinical profile of those at risk of dissection is emerging and includes the presence of congenital heart defects, aortic dilatation and hypertension."</div>
                
                
                <div class="evidence-explanation">This reference mentions hypertension as part of the clinical profile for those at risk of aortic dissection, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Stroke
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001297" target="_blank">
                                Stroke
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001297)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hypertension is a leading risk factor for both ischemic and hemorrhagic stroke</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10645696" target="_blank">PMID:10645696</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension is a leading cause of both stroke and heart disease."</div>
                
                
                <div class="evidence-explanation">The abstract explicitly states that hypertension is a leading cause of stroke, supporting the statement that hypertensive heart disease is occasionally associated with strokes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37980821" target="_blank">PMID:37980821</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension... for IS only."</div>
                
                
                <div class="evidence-explanation">The abstract mentions hypertension as a risk factor for ischemic stroke, supporting the statement that hypertensive heart disease is occasionally associated with strokes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36990309" target="_blank">PMID:36990309</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertensive disorders of pregnancy are associated with a long-term risk for... ischemic stroke or hemorrhagic stroke in later life."</div>
                
                
                <div class="evidence-explanation">The abstract indicates a significant association between hypertensive disorders and stroke, supporting the statement that hypertensive heart disease is occasionally associated with strokes.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Palpitations
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001962" target="_blank">
                                Palpitations
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001962)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Syncope
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001279" target="_blank">
                                Syncope
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001279)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Heart Failure Exacerbations
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001635" target="_blank">
                                Congestive heart failure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001635)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Left Ventricular Diastolic Dysfunction
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0025168" target="_blank">
                                Left ventricular diastolic dysfunction
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0025168)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often the earliest cardiac manifestation of hypertensive heart disease, preceding systolic dysfunction. Results from increased myocardial stiffness due to hypertrophy and fibrosis.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Concentric Left Ventricular Hypertrophy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001712" target="_blank">
                                Left ventricular hypertrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001712)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Affects &gt;20% of hypertensive individuals. Results from adaptive response to chronic pressure overload, but leads to increased stiffness and impaired relaxation.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Proteinuria
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000093" target="_blank">
                                Proteinuria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000093)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hypertension can cause and worsen kidney damage</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18677585" target="_blank">PMID:18677585</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension and proteinuria are common risk factors for cardiovascular morbidity and mortality, as well as for the progression of renal disease."</div>
                
                
                <div class="evidence-explanation">The literature indicates that hypertension is associated with proteinuria and the progression of renal disease, supporting the statement that hypertension can cause and worsen kidney damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1614065" target="_blank">PMID:1614065</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The number of patients developing end-stage renal disease (ESRD) as a consequence of hypertension is increasing and accounts for 25% of new cases of ESRD in the United States. However, the diagnosis of hypertensive ESRD is one of exclusion and no pathologic data corroborate this classification."</div>
                
                
                <div class="evidence-explanation">While the literature suggests a link between hypertension and end-stage renal disease, it also notes that the diagnosis is often one of exclusion and lacks definitive pathologic data.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7606639" target="_blank">PMID:7606639</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The kidney can be considered as both culprit and victim in the hypertensive process. Deranged renal function contributes to the development of arterial hypertension and of secondary vascular damage at the glomerular and arteriolar level and accounts for the development of progressive nephrosclerosis."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that hypertension can lead to renal damage, including proteinuria and nephrosclerosis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Respiratory
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dyspnea
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002094" target="_blank">
                                Dyspnea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002094)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Reduced Exercise Tolerance</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Heart Failure Exacerbations</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31472880" target="_blank">PMID:31472880</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertensive heart disease includes the development of diastolic dysfunction, left ventricular hypertrophy, and heart failure with preserved and reduced ejection fraction. The development of heart failure can occur because of complications of ischemic heart disease or from progression of..."</div>
                
                
                <div class="evidence-explanation">The reference mentions heart failure as a frequent complication of hypertensive heart disease, but it does not specifically address dyspnea.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15950133" target="_blank">PMID:15950133</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Dyspnea and leg effort are the major symptoms limiting exercise in healthy subjects and in patients with a variety of respiratory disorders."</div>
                
                
                <div class="evidence-explanation">While the reference discusses dyspnea as a symptom that limits exercise tolerance, it is not specific to hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37345800" target="_blank">PMID:37345800</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ventilatory efficiency is impaired people with hypertension without a diagnosis of heart failure versus normotensive individuals."</div>
                
                
                <div class="evidence-explanation">This reference implies that dyspnea could be an issue in hypertensive patients, which could lead to reduced exercise tolerance.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">6</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chest Pain
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                                Chest pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100749)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">May indicate underlying coronary artery disease</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35061769" target="_blank">PMID:35061769</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension was found in 45% of patients. Hypertensive patients were older, with a higher SIS, calcium score, and prevalence of comorbidities and statin therapy compared to the normotensive (all p&lt;0.05)."</div>
                
                
                <div class="evidence-explanation">Description supports the presence of cardiovascular phenotypes linked to hypertensive heart disease, such as varying levels of coronary artery involvement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37861255" target="_blank">PMID:37861255</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PH is more than a single clinical entity due to its complex mechanism in which more than one subgroup may develop over time in the same patient. This complex mechanism challenges us when diagnosing the patient and faces us with life-threatening complications."</div>
                
                
                <div class="evidence-explanation">Pulmonary hypertension can be linked to hypertensive heart disease and exhibits complex cardiovascular phenotypes, including potential complications visible in diagnostic criteria.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19863866" target="_blank">PMID:19863866</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema are common presenting complaints."</div>
                
                
                <div class="evidence-explanation">The snippet from the literature directly supports the statement that fatigue is commonly reported among patients with hypertensive heart disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chest Pain
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                                Chest pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100749)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">May indicate underlying coronary artery disease, which is accelerated by hypertension</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2959621" target="_blank">PMID:2959621</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Chest pain is a common complaint among hypertensive patients."</div>
                
                
                <div class="evidence-explanation">The literature supports that chest pain is common among hypertensive patients, but it does not specify the frequency as &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30066227" target="_blank">PMID:30066227</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Uncontrolled hypertension is one of the most common determinant for the persistently high burden of cardiovascular (CV) disease, mostly including coronary artery disease (CAD) and hospital admissions due to acute coronary events."</div>
                
                
                <div class="evidence-explanation">The literature supports that hypertension is linked to coronary artery disease, which can present with chest pain, but it does not specify the frequency as &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20932116" target="_blank">PMID:20932116</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Evidence of a link between headache symptoms and cardiovascular disease has rapidly grown in recent years and it is of utmost importance for the cardiologist and neurologist to be aware of this intimate connection."</div>
                
                
                <div class="evidence-explanation">The literature supports the link between cardiovascular disease and symptoms such as chest pain, but it does not specify the frequency as &#39;occasional&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31472888" target="_blank">PMID:31472888</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The authors discuss the natural history and pathogenesis of heart failure owing to hypertensive heart disease, reviewing the important role of left ventricular hypertrophy as the inciting process leading to diastolic dysfunction and heart failure with preserved ejection fraction."</div>
                
                
                <div class="evidence-explanation">The provided literature discusses the pathogenesis and progression of hypertensive heart disease but does not mention fatigue as a frequent symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29766272" target="_blank">PMID:29766272</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The aim of this study was to evaluate the cardio-protective effects of different drug classes in treated pediatric hypertensive patients."</div>
                
                
                <div class="evidence-explanation">This study focuses on the effects of different antihypertensive drugs on pediatric patients and does not address fatigue as a symptom of hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28541499" target="_blank">PMID:28541499</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertension (HTN) is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure."</div>
                
                
                <div class="evidence-explanation">The document discusses various complications of hypertension but does not mention fatigue as a frequent symptom of hypertensive heart disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Reduced Exercise Tolerance
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003546" target="_blank">
                                Exercise intolerance
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003546)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often due to impaired coronary flow reserve and microvascular dysfunction limiting oxygen delivery during exertion</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Microvascular Angina
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                                Chest pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100749)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Chest pain without obstructive coronary artery disease, due to coronary microvascular dysfunction and reduced flow reserve</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Reduced Coronary Flow Reserve
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Due to microvascular dysfunction and rarefaction, even without epicardial coronary artery disease. Measured by PET or invasive assessment. This is a functional abnormality rather than a structural phenotype.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antihypertensive Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000181" target="_blank">
                            MAXO:0000181
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15331316" target="_blank">PMID:15331316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Outcomes in HHD and HF are improved by antihypertensive drugs at any stage of the condition."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that lowering blood pressure is a key treatment in managing hypertensive heart disease by stating that outcomes in HHD and HF improve with antihypertensive drugs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32728994" target="_blank">PMID:32728994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk of atherosclerotic cardiovascular disease and death."</div>
                
                
                <div class="evidence-explanation">The abstract highlights the importance of lowering blood pressure to reduce cardiovascular diseases, indirectly supporting the management of hypertensive heart disease through antihypertensive therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31472890" target="_blank">PMID:31472890</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Management of hypertension reduces cardiovascular outcomes among patients with diabetes."</div>
                
                
                <div class="evidence-explanation">This reference adds support by emphasizing the general importance of hypertension management in reducing cardiovascular outcomes, which aligns with the prevention and management of hypertensive heart disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    ACE Inhibitors or ARBs
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000652" target="_blank">
                            MAXO:0000652
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line agents that reduce workload on the heart.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2485024" target="_blank">PMID:2485024</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There is evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors can play an important role in protecting the heart during the various phases of evolution of hypertensive heart disease both acutely and on a long-term basis."</div>
                
                
                <div class="evidence-explanation">ACE inhibitors have been shown to reduce cardiac hypertrophy and have protective effects on the heart during hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19588327" target="_blank">PMID:19588327</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85)."</div>
                
                
                <div class="evidence-explanation">ACE inhibitors are demonstrated to be effective in reducing cardiovascular events and mortality, which aligns with their role in reducing the workload on the heart.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31498767" target="_blank">PMID:31498767</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure."</div>
                
                
                <div class="evidence-explanation">Both ACE inhibitors and ARBs are indicated for multiple conditions related to heart workload reduction, including heart failure and hypertension conditions.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Beta Blockers
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000186" target="_blank">
                            MAXO:0000186
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8651834" target="_blank">PMID:8651834</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Beta-Blockers are widely used in cardiovascular medicine... Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction."</div>
                
                
                <div class="evidence-explanation">The abstract supports that beta-blockers are beneficial post-myocardial infarction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19615493" target="_blank">PMID:19615493</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Today, in patients with acute or chronic coronary syndromes or with congestive heart failure, reducing heart rate is a generally accepted treatment modality."</div>
                
                
                <div class="evidence-explanation">The abstract supports that reducing heart rate with beta-blockers is an accepted treatment in congestive heart failure, relevant to hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20539841" target="_blank">PMID:20539841</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers... beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients."</div>
                
                
                <div class="evidence-explanation">The abstract clearly supports the claim that beta-blockers help to control heart rate and are beneficial in post-myocardial infarction scenarios.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Diuretics
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Reduce fluid overload and congestion in heart failure.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24243991" target="_blank">PMID:24243991</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Diuretics have been recommended as first-line treatment of hypertension and are also valuable in the management of hypervolemia and electrolyte disorders."</div>
                
                
                <div class="evidence-explanation">The reference indicates that diuretics are important in the management of hypervolemia, which is a condition related to fluid overload.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19863866" target="_blank">PMID:19863866</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of diuretics in managing symptoms related to heart failure, including reducing fluid overload and congestion.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35165832" target="_blank">PMID:35165832</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"soluble guanylate cyclase stimulators are new classes of chemical agents that... have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D)."</div>
                
                
                <div class="evidence-explanation">Although the reference includes other treatments, it does mention the effectiveness of various drugs in treating heart failure which can include diuretics.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Mineralocorticoid Receptor Antagonists
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Further regulate fluid balance and have direct anti-fibrotic effects on the heart.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17362671" target="_blank">PMID:17362671</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade."</div>
                
                
                <div class="evidence-explanation">The reference discusses the vital importance of mineralocorticoid receptor antagonists in the treatment of cardiovascular conditions, implying their broad therapeutic potential, which can be interpreted as supporting fluid balance regulation and anti-fibrotic effects.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10904856" target="_blank">PMID:10904856</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The competitive aldosterone receptor antagonist, spironolactone, was able to prevent fibrosis in both ventricles in either model of arterial hypertension irrespective of the development of left ventricular hypertrophy and hypertension."</div>
                
                
                <div class="evidence-explanation">The text explicitly states that mineralocorticoid receptor antagonists like spironolactone can prevent fibrosis, providing supporting evidence for the statement&#39;s claim of direct anti-fibrotic effects.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35438025" target="_blank">PMID:35438025</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of subjects eplerenone was administered."</div>
                
                
                <div class="evidence-explanation">While this primarily discusses adherence, the context indicates widespread use of MR antagonists in managing hypertensive conditions, suggesting their relevance in regulating fluid balance and potential anti-fibrotic effects.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lifestyle Modifications
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Sodium restriction, physical activity, stress reduction, and other supportive measures.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3882040" target="_blank">PMID:3882040</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These therapies include weight reduction; sodium restriction; potassium, calcium, and magnesium supplementation; other dietary changes; exercise; relaxation; and moderation of alcohol use. Such therapies have been inadequately used, in part because of a lack of confidence in their effectiveness..."</div>
                
                
                <div class="evidence-explanation">The literature supports sodium restriction, physical activity (exercise), and relaxation (stress reduction) as part of the non-drug treatments for hypertension. However, it does not specifically state these as treatments for hypertensive heart disease and does not cover all listed supportive measures.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20937450" target="_blank">PMID:20937450</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD."</div>
                
                
                <div class="evidence-explanation">This literature mentions that therapeutic lifestyle changes are crucial for hypertensive heart disease (HHD). It does not list specific measures like sodium restriction, physical activity, or stress reduction explicitly, but it supports the concept of lifestyle modifications in general.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31756356" target="_blank">PMID:31756356</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Adopting healthy lifestyles, such as being active on &gt;/=4 days per week, weight-loss in the presence of obesity, consuming a diet rich in fruits and vegetables, and sodium below the recommended threshold, avoiding high alcohol consumption and refraining from smoking have been effective lifestyle..."</div>
                
                
                <div class="evidence-explanation">This literature supports that lifestyle modifications including physical activity, sodium restriction, and other supportive measures are effective for controlling hypertension. However, it does not mention hypertensive heart disease specifically.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Uncontrolled Hypertension</div>
                
                <div class="item-desc">Major risk factor and driver of disease progression</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19884691" target="_blank">PMID:19884691</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Left ventricular hypertrophy (LVH) has been shown to be a significant risk factor for adverse outcomes both in patients with hypertension and in the general population."</div>
                
                
                <div class="evidence-explanation">The literature indicates that uncontrolled hypertension is a significant driver of hypertensive heart disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Brain Natriuretic Peptide (BNP)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36533535" target="_blank">PMID:36533535</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Given the important role of cardiac injury and neurohormonal activation in the pathways leading from hypertension to heart failure... observed between hypertension and its sequelae on hs-cTnT (high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels..."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by discussing the association between hypertension (as seen in hypertensive heart disease) and elevated levels of NT-proBNP, which is a form of BNP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24015598" target="_blank">PMID:24015598</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cardiac hormone, B-type natriuretic peptide (BNP), is one of human natriuretic peptides which possesses cardiorenal protective actions and is used as a therapeutic and a biomarker for heart failure (HF)... circulating NT-proBNP and BNP are elevated in HF..."</div>
                
                
                <div class="evidence-explanation">This reference supports that BNP is elevated in conditions of heart failure, which can encompass hypertensive heart disease, highlighting its diagnostic role.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37712339" target="_blank">PMID:37712339</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure... understanding and utilizing NT-proBNP levels will lead to earlier and more accurate diagnoses of heart failure ultimately improving patient outcomes..."</div>
                
                
                <div class="evidence-explanation">It reinforces BNP&#39;s importance as a biomarker in heart failure, which can result from hypertensive heart disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Troponin
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29278556" target="_blank">PMID:29278556</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"High-sensitivity cardiac troponin T (hs-cTnT) values have been shown to be positively correlated with left ventricular hypertrophy in hypertensive patients."</div>
                
                
                <div class="evidence-explanation">The study confirms that troponin levels are elevated in patients with hypertensive heart disease, indicating myocardial injury.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35690315" target="_blank">PMID:35690315</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is associated with heart failure (HF) risk. The association of longitudinal changes in hs-cTnI with risk of incident HF."</div>
                
                
                <div class="evidence-explanation">This study highlights that elevated troponin levels are associated with increased risk of heart failure among patients with hypertensive heart disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11711527" target="_blank">PMID:11711527</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fibrous tissue accumulation is an integral feature of the adverse structural remodeling of cardiac tissue seen with hypertensive heart disease."</div>
                
                
                <div class="evidence-explanation">While the focus here is on myocardial fibrosis, it indirectly supports that biomarkers indicating myocardial injury, such as troponin, are relevant in hypertensive heart disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Hypertensive Heart Disease
category: Cardiovascular
parents:
- Hypertension
- Heart Disease
has_subtypes:
- name: Left Ventricular Hypertrophy
  description: Thickening of the heart&#39;s main pumping chamber (left ventricle) in
    response to high blood pressure.
  evidence:
  - reference: PMID:16097361
    supports: PARTIAL
    snippet: Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D)
      are the early manifestations of cardiovascular target organ damage in patients
      with arterial hypertension and signify hypertensive heart disease.
    explanation: The reference indicates that left ventricular hypertrophy (LVH) is
      a manifestation of hypertensive heart disease, but it does not explicitly state
      that LVH is a subtype of hypertensive heart disease. However, since it implies
      a direct relationship, partial support is inferred.
- name: Coronary Artery Disease
  description: Narrowing of the blood vessels that supply the heart, worsened by hypertension.
  evidence:
  - reference: PMID:37739329
    supports: SUPPORT
    snippet: Hypertension represents a major contributor to the development of coronary
      artery disease. The pathophysiological mechanisms underlying the link between
      hypertension and CAD are complex and include overactivation of neurohormones,
      accelerated development of the atherosclerotic plaque, endothelial dysfunction,
      altered intramyocardial coronary circulation, hypertension-mediated cardiac
      and vascular damage and the relationship between arterial stiffness and coronary
      perfusion.
    explanation: The literature explicitly mentions the contribution of hypertension
      to the development of coronary artery disease, which involves narrowing of the
      blood vessels that supply the heart.
- name: Heart Failure
  description: Weakening of the heart muscle, leading to reduced pumping efficiency,
    often as a result of long-standing hypertension.
  evidence:
  - reference: PMID:31472888
    supports: SUPPORT
    snippet: Hypertensive heart disease represents a spectrum of illnesses from uncontrolled
      hypertension to heart failure.
    explanation: The abstract indicates that heart failure can develop as part of
      hypertensive heart disease.
  - reference: PMID:36030347
    supports: SUPPORT
    snippet: Current evidence, based on cross-sectional and longitudinal observational
      studies as well as real-world registries and randomized controlled trials, suggests
      that women are more at risk of developing (and maintaining) LVH, concentric
      remodeling and subclinical LV dysfunction, namely the morpho-functional features
      of heart failure with preserved ejection fraction.
    explanation: The study supports the presence of heart failure as an outcome of
      hypertensive heart disease.
  - reference: PMID:35679365
    supports: SUPPORT
    snippet: Several factors chronically lead to HF, including cardiac volume and
      pressure overload that may result from hypertension.
    explanation: Heart failure as a result of hypertension is explicitly mentioned.
  - reference: PMID:27884237
    supports: SUPPORT
    snippet: Left ventricular (LV) diastolic dysfunction (LVDD) is characterized by
      alterations in LV diastolic filling, and is a strong predictor of cardiovascular
      events and heart failure. Hypertension is the most important risk factor for
      LVDD in the community and promotes LVDD through several mechanisms.
    explanation: Hypertension leading to heart failure is supported via the mechanism
      of LV diastolic dysfunction.
prevalence:
- population: Adults over 50
  percentage: 10-20
  evidence:
  - reference: PMID:35372212
    supports: REFUTE
    snippet: From 1990 to 2019, HHD prevalence in China showed decreasing trends in
      both sexes combined... but significant increases in the age groups of 15-19,
      20-24, ..., and 60-64 years.
    explanation: The study noted significant increasing trends in HHD prevalence in
      specific age groups, including older adults, but it did not provide specific
      percentage values within the 10-20 range for adults over 50. Instead, it indicates
      general trends rather than precise prevalence rates.
  - reference: PMID:9256850
    supports: NO_EVIDENCE
    snippet: &#39;CONCLUSIONS: Congestive heart failure is a major public health problem
      in the United States today as a result of its high and increasing prevalence
      in the older population...&#39;
    explanation: The reference discusses the prevalence and impact of congestive heart
      failure in older adults but does not offer specific statistics on the overall
      prevalence rate of hypertensive heart disease in the 10-20% range for adults
      over 50.
progression:
- phase: Asymptomatic
  age_range: 40-60
  evidence:
  - reference: PMID:38596912
    supports: SUPPORT
    snippet: This study documents the point prevalence of subclinical heart disease
      in emergency patients with asymptomatic hypertension.
    explanation: This reference supports the statement for the asymptomatic phase
      by documenting the presence of subclinical heart disease in patients with asymptomatic
      hypertension, which aligns with the concept of progression in hypertensive heart
      disease, but it does not focus specifically on the age range of 40-60.
- phase: Symptomatic
  age_range: 50-80
  evidence:
  - reference: PMID:21263005
    supports: PARTIAL
    snippet: The progression of hypertensive heart disease.
    explanation: The reference discusses the progression of hypertensive heart disease
      but does not specify the age range of 50-80 or the phase as symptomatic.
  - reference: PMID:38596912
    supports: NO_EVIDENCE
    snippet: Black, Hispanic, and female patients with asymptomatic hypertension are
      on the continuum for developing overt heart failure.
    explanation: The study focuses on the prevalence of subclinical heart disease
      in asymptomatic hypertensive patients, without specifying the age range of 50-80
      or mentioning symptomatic progression.
  - reference: PMID:37698022
    supports: PARTIAL
    snippet: In the past three decades, there has been an overall increasing trend
      in the prevalence of HHD among older adults worldwide.
    explanation: While the reference provides data about the prevalence and burden
      of hypertensive heart disease among older adults, it does not specifically address
      the symptomatic progression of the disease.
  - reference: PMID:34809918
    supports: SUPPORT
    snippet: Pulmonary hypertension (PH) due to left heart disease (LHD; group 2 PH)
      is a common complication of heart failure.
    explanation: The reference describes pulmonary hypertension due to left heart
      disease as a progression related to heart failure, which fits the description
      of symptomatic progression within the age range.
  - reference: PMID:35138872
    supports: NO_EVIDENCE
    snippet: The presence of HMOD confers incremental prognostic information regarding
      cardiovascular disease risk at every BP category.
    explanation: The study emphasizes the presence and prognosis of hypertension-mediated
      organ damage but does not detail the progression of hypertensive heart disease
      specifically within the 50-80 age range or the symptomatic phase.
pathophysiology:
- name: Increased Cardiac Workload
  description: Hypertension increases the pressure the heart must pump against, leading
    to cardiac remodeling and dysfunction over time.
  evidence:
  - reference: PMID:38428029
    supports: SUPPORT
    snippet: Pathologic cardiac hypertrophy is a common consequence of many cardiovascular
      diseases, including aortic stenosis (AS). AS is known to increase the pressure
      load of the left ventricle, causing a compensative response of the cardiac muscle,
      which progressively will lead to dilation and heart failure.
    explanation: This reference discusses the pressure load on the left ventricle
      due to aortic stenosis, leading to cardiac remodeling and dysfunction, supporting
      the described mechanism of hypertensive heart disease.
  - reference: PMID:7496052
    supports: SUPPORT
    snippet: Hypertension is associated with the remodeling of left ventricular geometry
      and abnormalities of function that may precede geometric changes. Rather than
      a specific disease, &#39;hypertensive heart failure&#39; is a spectrum of disorders
      that result from left ventricular geometric changes and comorbid conditions.
    explanation: The reference explains the remodeling of the left ventricle due to
      hypertension and the functional abnormalities that occur, supporting the described
      mechanism of hypertensive heart disease.
  - reference: PMID:19427497
    supports: SUPPORT
    snippet: LVDD as an early measure of myocardial end-organ damage is commonly associated
      with hypertension and may well precede development of LVH in hypertension.
    explanation: This reference discusses the association between hypertension and
      left ventricular dysfunction, an early indicator of cardiac remodeling and dysfunction,
      supporting the described mechanism.
  - reference: PMID:28082430
    supports: SUPPORT
    snippet: SHR had lower ejection fraction compared with WKY at all ages, but there
      was no difference in cardiac output at any age. At 21 month the SHR had significantly
      elevated stroke work (51 +/- 3 mL.mmHg SHR vs. 24 +/- 2 mL.mmHg WKY; n = 8,
      4; P &lt; 0.001) and cardiac minute work (14.2 +/- 1.2 L.mmHg/min SHR vs. 6.2 +/-
      0.8 L.mmHg/min WKY; n = 8, 4; P &lt; 0.001) compared to control, in addition to
      significantly larger left ventricular mass to body mass ratio (3.61 +/- 0.15
      mg/g SHR vs. 2.11 +/- 0.008 mg/g WKY; n = 8, 6; P &lt; 0.001).
    explanation: This study in spontaneously hypertensive rats shows increased cardiac
      work and hypertrophy, which aligns with the described mechanism of increased
      cardiac workload leading to dysfunction.
- name: Left Ventricular Hypertrophy
  description: The heart muscle thickens to cope with increased workload, but this
    can lead to stiffness and impaired filling.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  evidence:
  - reference: PMID:11062603
    supports: SUPPORT
    snippet: &#39;Sustained increase in arterial pressure causes left ventricular hypertrophy
      and adversely affects all myocardial compartments: myocytes, interstitium, and
      coronary vasculature.&#39;
    explanation: The paper discusses how hypertension causes left ventricular hypertrophy
      and affects multiple myocardial compartments.
  - reference: PMID:36933415
    supports: SUPPORT
    snippet: We computed both eccentric and concentric hypertrophy effects and tracked
      changes in the ventricle shape and wall thickness.
    explanation: The study confirms that changes in wall thickness and ventricular
      shape due to hypertrophy reflect an adaptation to increased workload.
  - reference: PMID:10652906
    supports: SUPPORT
    snippet: Left ventricular hypertrophy (LVH) is pathognomonic of HHD.
    explanation: Left ventricular hypertrophy is directly associated with hypertensive
      heart disease and involves thickening of the heart muscle.
  - reference: PMID:37827810
    supports: SUPPORT
    snippet: In case of hypertrophy, an increased influence of the dilating transmural
      fibre component might counteract systolic wall thickening, thereby counteract
      cardiac output.
    explanation: The reference discusses the influence of hypertrophy on wall thickening
      and heart function.
- name: Myocardial Ischemia
  description: Hypertension can worsen atherosclerosis in the coronary arteries, reducing
    blood flow to the heart muscle.
  evidence:
  - reference: PMID:37739329
    supports: SUPPORT
    snippet: Hypertension represents a major contributor to the development of coronary
      artery disease. The pathophysiological mechanisms underlying the link between
      hypertension and CAD are complex and include overactivation of neurohormones,
      accelerated development of the atherosclerotic plaque, endothelial dysfunction,
      altered intramyocardial coronary circulation...
    explanation: This reference outlines how hypertension can lead to coronary artery
      disease by affecting atherosclerotic plaque development, endothelial dysfunction,
      and coronary circulation, which are consistent with the statement.
  - reference: PMID:11062603
    supports: SUPPORT
    snippet: &#39;Sustained increase in arterial pressure causes left ventricular hypertrophy
      and adversely affects all myocardial compartments: myocytes, interstitium, and
      coronary vasculature. Ventricular hypertrophy significantly increases the risk
      for cardiovascular morbidity and mortality in hypertensive disease. Impairments
      in coronary circulation and ventricular fibrosis, which are an essential part
      of hypertensive disease...&#39;
    explanation: The report discusses the negative impact of hypertension on coronary
      circulation and the involvement of coronary vasculature impairments due to hypertensive
      disease, supporting the statement.
  - reference: PMID:33143256
    supports: SUPPORT
    snippet: Ischemic heart disease still represents a large burden on individuals
      and health care resources worldwide. By conventions, it is equated with atherosclerotic
      plaque due to flow-limiting obstruction in large-medium sized coronary arteries.
      However, clinical, angiographic and autoptic findings suggest a multifaceted
      pathophysiology for ischemic heart disease and just some cases are caused by
      severe or complicated atherosclerotic plaques.
    explanation: This reference explains that ischemic heart disease, which can result
      from severe atherosclerotic plaques, aligns with the statement that hypertension-induced
      atherosclerosis can reduce coronary blood flow, contributing to myocardial ischemia.
- name: Cardiac Fibrosis
  description: Chronic pressure overload stimulates fibroblasts to deposit excess
    collagen in the heart, stiffening it. TGF-Œ≤/SMAD signaling drives fibroblast-to-myofibroblast
    transition and increased collagen deposition.
  cell_types:
  - preferred_term: Cardiac Fibroblast
    term:
      id: CL:0002548
      label: fibroblast of cardiac tissue
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: collagen fibril organization
    term:
      id: GO:0030199
      label: collagen fibril organization
  locations:
  - preferred_term: myocardial interstitium
  - preferred_term: perivascular space
  evidence:
  - reference: PMID:37999643
    supports: SUPPORT
    snippet: In response to increased peripheral resistance in hypertension, intensified
      mechanical stretch in the myocardium induces cardiomyocyte hypertrophy and fibroblast
      activation to withstand increased pressure overload. This changes the structure
      and function of the heart, leading to pathological cardiac remodeling and eventual
      progression to heart failure.
    explanation: The activation of fibroblasts in response to hypertension and their
      role in cardiac remodeling aligns with the statement that chronic pressure overload
      stimulates fibroblasts to deposit excess collagen in the heart.
  - reference: PMID:33568808
    supports: SUPPORT
    snippet: Diffuse myocardial fibrosis resulting from the excessive deposition of
      collagen fibres through the entire myocardium is encountered in a number of
      chronic cardiac diseases. This lesion results from alterations in the regulation
      of fibrillary collagen turnover by fibroblasts, facilitating the excessive deposition
      of type I and type III collagen fibres within the myocardial interstitium and
      around intramyocardial vessels.
    explanation: This reference details how fibroblasts facilitate excessive collagen
      deposition in the myocardium, which supports the statement regarding cardiac
      fibrosis due to chronic pressure overload.
  - reference: PMID:2532916
    supports: SUPPORT
    snippet: In left ventricular pressure overload a reactive interstitial fibrosis,
      having distinctive biochemical and structural features, is seen. This reactive
      fibrosis occurs in the absence of myocyte necrosis, is progressive in nature,
      and initially is an adaptive response that preserves the force generating capacity,
      or active (systolic) stiffness, of the hypertrophied myocardium.
    explanation: The description of reactive interstitial fibrosis in response to
      pressure overload supports the statement about fibroblasts depositing excess
      collagen in the heart under chronic pressure overload conditions, leading to
      fibrosis and stiffening.
  - reference: PMID:10829097
    supports: SUPPORT
    snippet: Mechanisms underlying risk associated with hypertensive heart disease
      (HHD) and left ventricular hypertrophy (LVH) are discussed in this report and
      provide a rationale for understanding this very common and important cause of
      death from hypertension and its complications. Emphasized are impaired coronary
      hemodynamics, endothelial dysfunction, and ventricular fibrosis from increased
      collagen deposition intramurally and perivascularly.
    explanation: The mention of ventricular fibrosis due to increased collagen deposition
      supports the statement that chronic pressure overload results in fibroblasts
      depositing excess collagen, leading to cardiac fibrosis.
  - reference: PMID:33570899
    supports: SUPPORT
    snippet: The differentiation of TH17 cells reflected the cardiac hypertrophy and
      remodeling response to hypertension-induced pressure overload, and it might
      be a potential inflammatory marker to predict the prognosis of hypertensive
      patients.
    explanation: Although this snippet primarily focuses on TH17 cells, it indicates
      that remodeling due to hypertension includes elements of fibroblast activation
      and fibrosis.
- name: Coronary Microvascular Dysfunction
  description: Hypertension causes endothelial dysfunction, microvascular rarefaction,
    and perivascular fibrosis in the coronary microvasculature, reducing coronary
    flow reserve and oxygen delivery to the hypertrophied myocardium. This contributes
    to ischemia and progression to heart failure with preserved ejection fraction.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: pericyte
    term:
      id: CL:0000669
      label: pericyte
  biological_processes:
  - preferred_term: angiogenesis
    term:
      id: GO:0001525
      label: angiogenesis
  - preferred_term: regulation of nitric oxide biosynthetic process
    term:
      id: GO:0045428
      label: regulation of nitric oxide biosynthetic process
  locations:
  - preferred_term: coronary microvasculature
  notes: Pericyte loss and endothelial dysfunction lead to capillary rarefaction,
    which is a hallmark of hypertensive heart disease progression to HFpEF
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: NADPH oxidases (NOX2 and NOX4) generate reactive oxygen species in
    response to mechanical stress and Ang II signaling. This oxidative stress damages
    mitochondria, reduces ATP production, and activates pro-fibrotic signaling pathways
    including NF-Œ∫B.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: superoxide metabolic process
    term:
      id: GO:0006801
      label: superoxide metabolic process
  - preferred_term: mitochondrial electron transport
    term:
      id: GO:0006123
      label: mitochondrial electron transport, NADH to ubiquinone
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  notes: NOX2 (CYBB gene) and NOX4 are major enzymatic ROS sources linking mechanical
    and Ang II stimuli to oxidative damage
- name: Inflammasome Activation
  description: Pressure overload and oxidative stress activate the NLRP3 inflammasome,
    leading to caspase-1 activation and release of IL-1Œ≤ and IL-18. This inflammatory
    signaling amplifies cardiac fibrosis, hypertrophy, and adverse remodeling.
  biological_processes:
  - preferred_term: inflammasome complex assembly
    term:
      id: GO:0061702
      label: inflammasome complex assembly
  - preferred_term: interleukin-1 beta production
    term:
      id: GO:0032611
      label: interleukin-1 beta production
  notes: NLRP3 inflammasome activation promotes pyroptosis and chronic inflammation
    in hypertensive heart disease
phenotypes:
- category: Cardiovascular
  name: Dyspnea
  frequency: FREQUENT
  sequelae:
  - target: Reduced Exercise Tolerance
  - target: Heart Failure Exacerbations
  evidence:
  - reference: PMID:31472880
    supports: PARTIAL
    snippet: Hypertensive heart disease includes the development of diastolic dysfunction,
      left ventricular hypertrophy, and heart failure with preserved and reduced ejection
      fraction. The development of heart failure can occur because of complications
      of ischemic heart disease or from progression of diastolic dysfunction to heart
      failure with preserved ejection fraction degenerating to a dilated heart with
      systolic dysfunction or heart failure with reduced ejection fraction.
    explanation: The reference mentions heart failure as a frequent complication of
      hypertensive heart disease, but it does not specifically address dyspnea.
  - reference: PMID:15950133
    supports: PARTIAL
    snippet: Dyspnea and leg effort are the major symptoms limiting exercise in healthy
      subjects and in patients with a variety of respiratory disorders.
    explanation: While the reference discusses dyspnea as a symptom that limits exercise
      tolerance, it is not specific to hypertensive heart disease.
  - reference: PMID:37345800
    supports: SUPPORT
    snippet: Ventilatory efficiency is impaired people with hypertension without a
      diagnosis of heart failure versus normotensive individuals.
    explanation: This reference implies that dyspnea could be an issue in hypertensive
      patients, which could lead to reduced exercise tolerance.
  - reference: PMID:26569571
    supports: PARTIAL
    snippet: Pulmonary hypertension (PH) due to left-sided heart disease (LSHD) is
      a common and disconcerting occurrence. For example, both heart failure (HF)
      with preserved and reduced ejection fraction (HFpEF and HFrEF) often lead to
      PH as a consequence of a chronic elevation in left atrial filling pressure.
    explanation: It mentions heart failure and its link to dyspnea indirectly through
      pulmonary hypertension but does not focus on hypertensive heart disease specifically.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Cardiovascular
  name: Chest Pain
  frequency: OCCASIONAL
  notes: May indicate underlying coronary artery disease
  evidence:
  - reference: PMID:35061769
    supports: SUPPORT
    snippet: Hypertension was found in 45% of patients. Hypertensive patients were
      older, with a higher SIS, calcium score, and prevalence of comorbidities and
      statin therapy compared to the normotensive (all p&lt;0.05).
    explanation: Description supports the presence of cardiovascular phenotypes linked
      to hypertensive heart disease, such as varying levels of coronary artery involvement.
  - reference: PMID:37861255
    supports: SUPPORT
    snippet: PH is more than a single clinical entity due to its complex mechanism
      in which more than one subgroup may develop over time in the same patient. This
      complex mechanism challenges us when diagnosing the patient and faces us with
      life-threatening complications.
    explanation: Pulmonary hypertension can be linked to hypertensive heart disease
      and exhibits complex cardiovascular phenotypes, including potential complications
      visible in diagnostic criteria.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Cardiovascular
  name: Arrhythmias
  frequency: OCCASIONAL
  sequelae:
  - target: Palpitations
  - target: Syncope
  evidence:
  - reference: PMID:34809918
    supports: PARTIAL
    snippet: PH due to LHD is associated with negative impact on outcomes in addition
      to worse symptoms and exercise capacity.
    explanation: While this supports the cardiovascular phenotype in the context of
      arrhythmias, it does not specifically mention palpitations or syncope as sequelae
      of hypertensive heart disease.
  - reference: PMID:36202538
    supports: PARTIAL
    snippet: Evaluation of cardiac phenotypes in secondary hypertension provides a
      unique opportunity to study underlying hormonal and biochemical mechanisms affecting
      the heart.
    explanation: This implies a variety of cardiac phenotypes can be seen in hypertension
      but does not explicitly list arrhythmias, palpitations, or syncope.
  phenotype_term:
    preferred_term: Arrhythmias
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Systemic
  name: Fatigue
  frequency: FREQUENT
  evidence:
  - reference: PMID:19863866
    supports: SUPPORT
    snippet: Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema are
      common presenting complaints.
    explanation: The snippet from the literature directly supports the statement that
      fatigue is commonly reported among patients with hypertensive heart disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Chest Pain
  notes: May indicate underlying coronary artery disease, which is accelerated by
    hypertension
  evidence:
  - reference: PMID:2959621
    supports: PARTIAL
    snippet: Chest pain is a common complaint among hypertensive patients.
    explanation: The literature supports that chest pain is common among hypertensive
      patients, but it does not specify the frequency as &#39;occasional&#39;.
  - reference: PMID:30066227
    supports: PARTIAL
    snippet: Uncontrolled hypertension is one of the most common determinant for the
      persistently high burden of cardiovascular (CV) disease, mostly including coronary
      artery disease (CAD) and hospital admissions due to acute coronary events.
    explanation: The literature supports that hypertension is linked to coronary artery
      disease, which can present with chest pain, but it does not specify the frequency
      as &#39;occasional&#39;.
  - reference: PMID:20932116
    supports: PARTIAL
    snippet: Evidence of a link between headache symptoms and cardiovascular disease
      has rapidly grown in recent years and it is of utmost importance for the cardiologist
      and neurologist to be aware of this intimate connection.
    explanation: The literature supports the link between cardiovascular disease and
      symptoms such as chest pain, but it does not specify the frequency as &#39;occasional&#39;.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Arrhythmias
  sequelae:
  - target: Palpitations
  - target: Syncope
  notes: Arrhythmias like atrial fibrillation are more common in hypertensive heart
    disease
  evidence:
  - reference: PMID:31472889
    supports: PARTIAL
    snippet: Hypertensive heart disease can manifest as cardiac arrhythmias. Supraventricular
      and ventricular arrhythmias may occur in the hypertensive patients.
    explanation: The literature supports that hypertensive heart disease can manifest
      as arrhythmias, but it does not specifically address the frequency as &#39;occasional&#39;.
  - reference: PMID:36519436
    supports: PARTIAL
    snippet: Hypertension is prevalent in &gt;70% of atrial fibrillation patients. In
      turn, hypertensive patients have up to 73% greater likelihood of atrial fibrillation.
    explanation: The literature supports the association between hypertension and
      atrial fibrillation but does not specify the frequency of arrhythmias in hypertensive
      heart disease as &#39;occasional&#39;.
  phenotype_term:
    preferred_term: Arrhythmias
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Aortic Dissection
  notes: Hypertension is a major risk factor for aortic dissection
  evidence:
  - reference: PMID:11419663
    supports: SUPPORT
    snippet: Essential treatment includes rapid initiation of pharmacologic agents
      to control hypertension.
    explanation: This reference indicates that controlling hypertension is essential
      in the treatment of aortic dissection, supporting the notion that hypertension
      is a major risk factor for aortic dissection.
  - reference: PMID:25620633
    supports: SUPPORT
    snippet: In this review, we discuss cardiovascular hypertensive emergencies, including
      acute coronary syndrome, aortic dissection, congestive heart failure, and sympathomimetic
      hypertensive crises.
    explanation: This reference discusses aortic dissection as a cardiovascular hypertensive
      emergency, supporting the statement that hypertension is a major risk factor
      for aortic dissection.
  - reference: PMID:25573747
    supports: SUPPORT
    snippet: A clinical profile of those at risk of dissection is emerging and includes
      the presence of congenital heart defects, aortic dilatation and hypertension.
    explanation: This reference mentions hypertension as part of the clinical profile
      for those at risk of aortic dissection, supporting the statement.
  - reference: PMID:27873227
    supports: PARTIAL
    snippet: Even though arterial hypertension is commonly regarded as a predisposing
      condition for the development of thoracic aorta aneurysms, the role of blood
      pressure (BP) as determinant of aortic root enlargement is still controversial.
    explanation: This reference acknowledges that hypertension is commonly regarded
      as a predisposing condition for aortic diseases but notes some controversy regarding
      its role, providing partial support.
  - reference: PMID:23993245
    supports: SUPPORT
    snippet: Similar to other acute cardiovascular events (e.g., acute myocardial
      infarction, sudden death, stroke, and pulmonary embolism) there is a growing
      body of evidence regarding temporal patterns in onset, characterized by circadian,
      seasonal and weekly variations for aortic aneurysms.
    explanation: This reference discusses aortic dissection within the context of
      other cardiovascular events and mentions hypertension as a common underlying
      pathophysiologic mechanism, supporting the statement.
  phenotype_term:
    preferred_term: Aortic Dissection
    term:
      id: HP:0002647
      label: Aortic dissection
- category: Neurologic
  frequency: OCCASIONAL
  name: Stroke
  notes: Hypertension is a leading risk factor for both ischemic and hemorrhagic stroke
  evidence:
  - reference: PMID:10645696
    supports: SUPPORT
    snippet: Hypertension is a leading cause of both stroke and heart disease.
    explanation: The abstract explicitly states that hypertension is a leading cause
      of stroke, supporting the statement that hypertensive heart disease is occasionally
      associated with strokes.
  - reference: PMID:37980821
    supports: SUPPORT
    snippet: Hypertension... for IS only.
    explanation: The abstract mentions hypertension as a risk factor for ischemic
      stroke, supporting the statement that hypertensive heart disease is occasionally
      associated with strokes.
  - reference: PMID:36990309
    supports: SUPPORT
    snippet: Hypertensive disorders of pregnancy are associated with a long-term risk
      for... ischemic stroke or hemorrhagic stroke in later life.
    explanation: The abstract indicates a significant association between hypertensive
      disorders and stroke, supporting the statement that hypertensive heart disease
      is occasionally associated with strokes.
  - reference: PMID:29869130
    supports: SUPPORT
    snippet: Arterial hypertension represents the most important risk factor for ischemic
      and haemorrhagic stroke.
    explanation: This abstract clearly supports the statement that hypertensive heart
      disease is occasionally associated with strokes.
  - reference: PMID:32224751
    supports: SUPPORT
    snippet: Risk factor modification plays a large role in stroke prevention. Strategies
      for early intervention, particularly for hypertension, are critical for reducing
      stroke morbidity and mortality.
    explanation: The abstract supports the role of hypertension as a risk factor for
      stroke, aligning with the statement that hypertensive heart disease is occasionally
      associated with strokes.
  - reference: PMID:24080990
    supports: SUPPORT
    snippet: Apart from the well-known role of hypertension in cerebrovascular disease...
      an independent risk factor for stroke.
    explanation: This abstract confirms the role of hypertension as a risk factor
      for stroke, supporting the statement that hypertensive heart disease is occasionally
      associated with strokes.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:31472888
    supports: NO_EVIDENCE
    snippet: The authors discuss the natural history and pathogenesis of heart failure
      owing to hypertensive heart disease, reviewing the important role of left ventricular
      hypertrophy as the inciting process leading to diastolic dysfunction and heart
      failure with preserved ejection fraction.
    explanation: The provided literature discusses the pathogenesis and progression
      of hypertensive heart disease but does not mention fatigue as a frequent symptom.
  - reference: PMID:29766272
    supports: NO_EVIDENCE
    snippet: The aim of this study was to evaluate the cardio-protective effects of
      different drug classes in treated pediatric hypertensive patients.
    explanation: This study focuses on the effects of different antihypertensive drugs
      on pediatric patients and does not address fatigue as a symptom of hypertensive
      heart disease.
  - reference: PMID:28541499
    supports: NO_EVIDENCE
    snippet: Hypertension (HTN) is a common cardiovascular risk factor leading to
      heart failure (HF), coronary artery disease (CAD), stroke, peripheral artery
      disease and chronic renal failure.
    explanation: The document discusses various complications of hypertension but
      does not mention fatigue as a frequent symptom of hypertensive heart disease.
  - reference: PMID:17593316
    supports: NO_EVIDENCE
    snippet: Heart rate is an independent risk factor for patients with cardiovascular
      disease, in particular with arterial hypertension, myocardial infarction, coronary
      artery disease and heart failure.
    explanation: This article focuses on the role of heart rate in cardiovascular
      diseases but does not mention fatigue as a frequent symptom of hypertensive
      heart disease.
  - reference: PMID:23732143
    supports: NO_EVIDENCE
    snippet: Hypertension is strongly associated with overall cardiovascular risk.
      Increased blood pressure contributes to cardiovascular and cerebrovascular endpoints,
      such as myocardial infarction, heart failure, cardiovascular death and stroke.
    explanation: The literature describes the risks associated with hypertension but
      does not mention fatigue as a frequent symptom of hypertensive heart disease.
  - reference: PMID:38597067
    supports: NO_EVIDENCE
    snippet: We now have compelling evidence for a key role of sympathetic overactivity
      in the pathogenesis and progression of hypertension and associated hypertension-mediated
      organ damage (such as endothelial dysfunction, arterial stiffness and left ventricular
      hypertrophy).
    explanation: The literature discusses the role of sympathetic overactivity in
      hypertension and its complications but does not mention fatigue as a frequent
      symptom of hypertensive heart disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Renal
  frequency: FREQUENT
  name: Proteinuria
  notes: Hypertension can cause and worsen kidney damage
  evidence:
  - reference: PMID:18677585
    supports: SUPPORT
    snippet: Hypertension and proteinuria are common risk factors for cardiovascular
      morbidity and mortality, as well as for the progression of renal disease.
    explanation: The literature indicates that hypertension is associated with proteinuria
      and the progression of renal disease, supporting the statement that hypertension
      can cause and worsen kidney damage.
  - reference: PMID:1614065
    supports: PARTIAL
    snippet: The number of patients developing end-stage renal disease (ESRD) as a
      consequence of hypertension is increasing and accounts for 25% of new cases
      of ESRD in the United States. However, the diagnosis of hypertensive ESRD is
      one of exclusion and no pathologic data corroborate this classification.
    explanation: While the literature suggests a link between hypertension and end-stage
      renal disease, it also notes that the diagnosis is often one of exclusion and
      lacks definitive pathologic data.
  - reference: PMID:7606639
    supports: SUPPORT
    snippet: The kidney can be considered as both culprit and victim in the hypertensive
      process. Deranged renal function contributes to the development of arterial
      hypertension and of secondary vascular damage at the glomerular and arteriolar
      level and accounts for the development of progressive nephrosclerosis.
    explanation: This reference supports the statement by indicating that hypertension
      can lead to renal damage, including proteinuria and nephrosclerosis.
  - reference: PMID:20400279
    supports: SUPPORT
    snippet: With ongoing progression and glomerular extracapillary proliferation,
      tubulointerstitial damage occurs with consequent nephron loss and development
      of fibrotic lesions, finally resulting in terminal renal failure.
    explanation: The literature supports the statement by discussing how glomerular
      injury, often exacerbated by conditions like hypertension, leads to further
      renal damage and proteinuria.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
- category: Cardiovascular
  name: Reduced Exercise Tolerance
  frequency: FREQUENT
  notes: Often due to impaired coronary flow reserve and microvascular dysfunction
    limiting oxygen delivery during exertion
  phenotype_term:
    preferred_term: Reduced Exercise Tolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
- category: Cardiovascular
  name: Microvascular Angina
  frequency: OCCASIONAL
  notes: Chest pain without obstructive coronary artery disease, due to coronary
    microvascular dysfunction and reduced flow reserve
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Cardiovascular
  name: Palpitations
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Palpitations
    term:
      id: HP:0001962
      label: Palpitations
- category: Cardiovascular
  name: Syncope
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
- name: Heart Failure Exacerbations
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Heart Failure Exacerbations
    term:
      id: HP:0001635
      label: Congestive heart failure
- category: Cardiovascular
  name: Left Ventricular Diastolic Dysfunction
  frequency: VERY_FREQUENT
  notes: Often the earliest cardiac manifestation of hypertensive heart disease,
    preceding systolic dysfunction. Results from increased myocardial stiffness due
    to hypertrophy and fibrosis.
  phenotype_term:
    preferred_term: Left ventricular diastolic dysfunction
    term:
      id: HP:0025168
      label: Left ventricular diastolic dysfunction
- category: Cardiovascular
  name: Concentric Left Ventricular Hypertrophy
  frequency: VERY_FREQUENT
  notes: Affects &gt;20% of hypertensive individuals. Results from adaptive response
    to chronic pressure overload, but leads to increased stiffness and impaired relaxation.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
- category: Cardiovascular
  name: Reduced Coronary Flow Reserve
  frequency: FREQUENT
  notes: Due to microvascular dysfunction and rarefaction, even without epicardial
    coronary artery disease. Measured by PET or invasive assessment. This is a functional
    abnormality rather than a structural phenotype.
biochemical:
- name: Brain Natriuretic Peptide (BNP)
  presence: Elevated
  notes: Marker of cardiac stretch and heart failure
  evidence:
  - reference: PMID:36533535
    supports: SUPPORT
    snippet: Given the important role of cardiac injury and neurohormonal activation
      in the pathways leading from hypertension to heart failure... observed between
      hypertension and its sequelae on hs-cTnT (high-sensitivity cardiac troponin
      T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels...
    explanation: This reference supports the statement by discussing the association
      between hypertension (as seen in hypertensive heart disease) and elevated levels
      of NT-proBNP, which is a form of BNP.
  - reference: PMID:24015598
    supports: SUPPORT
    snippet: The cardiac hormone, B-type natriuretic peptide (BNP), is one of human
      natriuretic peptides which possesses cardiorenal protective actions and is used
      as a therapeutic and a biomarker for heart failure (HF)... circulating NT-proBNP
      and BNP are elevated in HF...
    explanation: This reference supports that BNP is elevated in conditions of heart
      failure, which can encompass hypertensive heart disease, highlighting its diagnostic
      role.
  - reference: PMID:37712339
    supports: SUPPORT
    snippet: Natriuretic peptides (NPs) have been recognized as important biomarkers
      for diagnosing heart failure... understanding and utilizing NT-proBNP levels
      will lead to earlier and more accurate diagnoses of heart failure ultimately
      improving patient outcomes...
    explanation: It reinforces BNP&#39;s importance as a biomarker in heart failure, which
      can result from hypertensive heart disease.
  - reference: PMID:16121315
    supports: SUPPORT
    snippet: Studies in patients with pulmonary arterial hypertension (PAH) have demonstrated
      that plasma BNP levels are raised proportionally to the extent of right ventricular
      (RV) dysfunction.
    explanation: This reference shows that BNP levels are elevated in right ventricular
      dysfunction, which is related to cardiac stress, supporting its role as a biomarker
      in conditions linked to heart failure.
- name: Troponin
  presence: Elevated
  notes: May indicate myocardial injury in acute decompensation
  evidence:
  - reference: PMID:29278556
    supports: SUPPORT
    snippet: High-sensitivity cardiac troponin T (hs-cTnT) values have been shown
      to be positively correlated with left ventricular hypertrophy in hypertensive
      patients.
    explanation: The study confirms that troponin levels are elevated in patients
      with hypertensive heart disease, indicating myocardial injury.
  - reference: PMID:35690315
    supports: SUPPORT
    snippet: Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is
      associated with heart failure (HF) risk. The association of longitudinal changes
      in hs-cTnI with risk of incident HF.
    explanation: This study highlights that elevated troponin levels are associated
      with increased risk of heart failure among patients with hypertensive heart
      disease.
  - reference: PMID:11711527
    supports: PARTIAL
    snippet: Fibrous tissue accumulation is an integral feature of the adverse structural
      remodeling of cardiac tissue seen with hypertensive heart disease.
    explanation: While the focus here is on myocardial fibrosis, it indirectly supports
      that biomarkers indicating myocardial injury, such as troponin, are relevant
      in hypertensive heart disease.
  - reference: PMID:25052897
    supports: PARTIAL
    snippet: Increased plasma CT-1 levels are associated with risk for HF in hypertensive
      patients.
    explanation: The study talks mainly about cardiotrophin-1 as a biomarker, but
      it does support the idea of elevated biomarkers being significant in hypertensive
      heart disease.
diagnosis:
- name: Echocardiogram
  notes: Shows left ventricular hypertrophy, systolic and diastolic dysfunction
  evidence:
  - reference: PMID:10652906
    supports: PARTIAL
    snippet: Echo-Doppler study is the modality of choice to document cardiac involvement
      in hypertension.
    explanation: The reference indicates that Echocardiography (Echo-Doppler) is pivotal
      in diagnosing Hypertensive Heart Disease (HHD) as it can document cardiac involvement.
      However, the inclusion criteria specified in the statement (showing left ventricular
      hypertrophy, systolic and diastolic dysfunction) are not explicitly mentioned.
  - reference: PMID:32476157
    supports: SUPPORT
    snippet: Left ventricular (LV) diastolic function can be most conveniently assessed
      by echocardiography which provides reliable assessments of LV structure and
      function.
    explanation: This reference supports the statement by indicating that echocardiography
      is useful in assessing both diastolic and systolic functions as well as left
      ventricular structural changes, including hypertrophy, which are related to
      hypertensive heart disease.
  - reference: PMID:29964160
    supports: SUPPORT
    snippet: Diastolic dysfunction even without hypertrophy is often the first and
      only presentation in hypertension.
    explanation: This supports the notion that echocardiography can diagnose both
      diastolic dysfunction and hypertrophic changes in patients with hypertension,
      as those are presentations of hypertensive heart disease.
  - reference: PMID:34426850
    supports: SUPPORT
    snippet: We hypothesized that children with HTN would have left ventricular (LV)
      hypertrophy and abnormal LV global longitudinal strain (GLS) on echocardiogram.
    explanation: This study confirms the diagnostic capability of echocardiography
      in identifying left ventricular hypertrophy and dysfunction in hypertensive
      patients.
  - reference: PMID:23836799
    supports: SUPPORT
    snippet: Patients with stage 3 or greater chronic kidney disease have a high prevalence
      of left ventricular (LV) hypertrophy and diastolic dysfunction.
    explanation: This reference shows a relationship between hypertensive conditions
      and echocardiographic findings of LV hypertrophy and diastolic dysfunction.
- name: Electrocardiogram (ECG)
  notes: May show signs of left ventricular hypertrophy, ischemia, or arrhythmia
  evidence:
  - reference: PMID:23022303
    supports: SUPPORT
    snippet: ECG remains the first line method for detection of left ventricular hypertrophy
      (LVH) in patients with hypertension.
    explanation: The literature confirms that ECG is used in the diagnosis of LVH,
      a key feature of hypertensive heart disease.
  - reference: PMID:10652906
    supports: SUPPORT
    snippet: Radiology of chest and electrocardiography (ECG) are highly insensitive.
      Magnetic resonance imaging (MRI) produces similar results like echo but is not
      cost-effective.
    explanation: This study supports the utility of ECG in diagnosing cardiac involvement
      in hypertension, though it notes some limitations in sensitivity.
  - reference: PMID:29964160
    supports: SUPPORT
    snippet: Diastolic dysfunction even without hypertrophy is often the first and
      only presentation in hypertension.
    explanation: The study highlights the role of ECG in detecting diastolic dysfunction,
      relevant to diagnosing hypertensive heart disease.
  - reference: PMID:8326666
    supports: PARTIAL
    explanation: No specific details provided in the literature.
  - reference: PMID:7495217
    supports: PARTIAL
    snippet: Hypertensive cardiomyopathies can be divided into 4 ascending categories,
      according to the pathophysiologic and clinical impact of hypertension on the
      heart.
    explanation: The literature describes different stages of hypertensive cardiomyopathy
      and their diagnosis but does not specifically mention ECG.
  - reference: PMID:32404601
    supports: SUPPORT
    snippet: A quarter of patients identified as having elevated blood pressure or
      stage 1 hypertension have structural heart disease. Screening echocardiograms
      may help to risk stratify those patients deemed ineligible for treatment.
    explanation: Indicates the use of ECG screening for identifying structural heart
      diseases in patients with hypertension.
  - reference: PMID:36913785
    supports: NO_EVIDENCE
    explanation: Focused on pulmonary hypertension and its diagnosis using ECG, not
      hypertensive heart disease.
  - reference: PMID:37624446
    supports: NO_EVIDENCE
    explanation: Study focused on chronic kidney disease patients and their cardiovascular
      risks.
environmental:
- name: Uncontrolled Hypertension
  notes: Major risk factor and driver of disease progression
  evidence:
  - reference: PMID:19884691
    supports: SUPPORT
    snippet: Left ventricular hypertrophy (LVH) has been shown to be a significant
      risk factor for adverse outcomes both in patients with hypertension and in the
      general population.
    explanation: The literature indicates that uncontrolled hypertension is a significant
      driver of hypertensive heart disease.
treatments:
- name: Antihypertensive Therapy
  description: Lowering blood pressure is the mainstay of treatment to prevent and
    manage hypertensive heart disease.
  evidence:
  - reference: PMID:15331316
    supports: SUPPORT
    snippet: Outcomes in HHD and HF are improved by antihypertensive drugs at any
      stage of the condition.
    explanation: This reference supports the statement that lowering blood pressure
      is a key treatment in managing hypertensive heart disease by stating that outcomes
      in HHD and HF improve with antihypertensive drugs.
  - reference: PMID:32728994
    supports: SUPPORT
    snippet: Extensive evidence demonstrates that lowering blood pressure can substantially
      reduce the risk of atherosclerotic cardiovascular disease and death.
    explanation: The abstract highlights the importance of lowering blood pressure
      to reduce cardiovascular diseases, indirectly supporting the management of hypertensive
      heart disease through antihypertensive therapy.
  - reference: PMID:31472890
    supports: SUPPORT
    snippet: Management of hypertension reduces cardiovascular outcomes among patients
      with diabetes.
    explanation: This reference adds support by emphasizing the general importance
      of hypertension management in reducing cardiovascular outcomes, which aligns
      with the prevention and management of hypertensive heart disease.
  treatment_term:
    preferred_term: cardiovascular agent therapy
    term:
      id: MAXO:0000181
      label: cardiovascular agent therapy
- name: ACE Inhibitors or ARBs
  description: First-line agents that reduce workload on the heart.
  evidence:
  - reference: PMID:2485024
    supports: SUPPORT
    snippet: There is evidence to suggest that angiotensin-converting enzyme (ACE)
      inhibitors can play an important role in protecting the heart during the various
      phases of evolution of hypertensive heart disease both acutely and on a long-term
      basis.
    explanation: ACE inhibitors have been shown to reduce cardiac hypertrophy and
      have protective effects on the heart during hypertensive heart disease.
  - reference: PMID:19588327
    supports: SUPPORT
    snippet: ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95),
      stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS
      (RR 0.76, 95% CI 0.67-0.85).
    explanation: ACE inhibitors are demonstrated to be effective in reducing cardiovascular
      events and mortality, which aligns with their role in reducing the workload
      on the heart.
  - reference: PMID:31498767
    supports: SUPPORT
    snippet: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor
      blockers (ARBs) are used primarily to treat hypertension and are also useful
      for conditions such as heart failure and chronic kidney disease, independent
      of their effect on blood pressure.
    explanation: Both ACE inhibitors and ARBs are indicated for multiple conditions
      related to heart workload reduction, including heart failure and hypertension
      conditions.
  - reference: PMID:26968600
    supports: SUPPORT
    snippet: Management guidelines categorise angiotensin-converting enzyme inhibitors
      (ACEI) and angiotensin receptor blockers (ARB) interchangeably as first-line
      treatments in uncomplicated hypertension.
    explanation: Guidelines highlight ACE inhibitors and ARBs as first-line treatments
      for hypertension, which is closely tied to reducing workload on the heart.
  treatment_term:
    preferred_term: ACE inhibitor therapy
    term:
      id: MAXO:0000652
      label: ACE inhibitor therapy
- name: Beta Blockers
  description: Help control heart rate, reduce oxygen demand, and are especially beneficial
    after a myocardial infarction.
  evidence:
  - reference: PMID:8651834
    supports: SUPPORT
    snippet: Beta-Blockers are widely used in cardiovascular medicine... Based on
      evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone
      of therapy after acute myocardial infarction.
    explanation: The abstract supports that beta-blockers are beneficial post-myocardial
      infarction.
  - reference: PMID:19615493
    supports: SUPPORT
    snippet: Today, in patients with acute or chronic coronary syndromes or with congestive
      heart failure, reducing heart rate is a generally accepted treatment modality.
    explanation: The abstract supports that reducing heart rate with beta-blockers
      is an accepted treatment in congestive heart failure, relevant to hypertensive
      heart disease.
  - reference: PMID:20539841
    supports: SUPPORT
    snippet: One successful way of decreasing HR and cardiovascular mortality has
      been by utilizing beta-blockers... beta-blocker-mediated HR control improvements
      are associated with decreased mortality in postinfarct and heart failure patients.
    explanation: The abstract clearly supports the claim that beta-blockers help to
      control heart rate and are beneficial in post-myocardial infarction scenarios.
  - reference: PMID:28402023
    supports: SUPPORT
    snippet: Combination of beta-blocker therapy with ET does not compromise the effect
      of training and instead promotes HRR and aerobic capacity improvement... However,
      chronic administration of beta-blocker therapy alone did not promote improvement
      in HRR or aerobic capacity.
    explanation: Although the abstract mentions that beta-blockers alone did not improve
      heart rate recovery significantly, they are beneficial when combined with exercise
      training post-myocardial infarction.
  - reference: PMID:140280
    supports: SUPPORT
    snippet: Regardless of the level of arterial pressure, vasodilator drugs that
      lower arterial pressure may result in marked improvement in left ventricular
      performance and relief of symptoms of left ventricular failure.
    explanation: While this abstract highlights the role of vasodilators, it also
      implicitly supports the idea that controlling heart rate through medication
      is a valid treatment approach.
  treatment_term:
    preferred_term: beta adrenergic agent therapy
    term:
      id: MAXO:0000186
      label: beta adrenergic agent therapy
- name: Diuretics
  description: Reduce fluid overload and congestion in heart failure.
  evidence:
  - reference: PMID:24243991
    supports: SUPPORT
    snippet: Diuretics have been recommended as first-line treatment of hypertension
      and are also valuable in the management of hypervolemia and electrolyte disorders.
    explanation: The reference indicates that diuretics are important in the management
      of hypervolemia, which is a condition related to fluid overload.
  - reference: PMID:19863866
    supports: SUPPORT
    snippet: In patients with established heart failure, diuretics and other empiric
      treatments are used to control symptoms.
    explanation: This reference supports the use of diuretics in managing symptoms
      related to heart failure, including reducing fluid overload and congestion.
  - reference: PMID:35165832
    supports: SUPPORT
    snippet: soluble guanylate cyclase stimulators are new classes of chemical agents
      that... have been shown to be effective for the treatment of cardiovascular
      (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D).
    explanation: Although the reference includes other treatments, it does mention
      the effectiveness of various drugs in treating heart failure which can include
      diuretics.
  - reference: PMID:35190215
    supports: SUPPORT
    snippet: Diuretics are the cornerstone of therapy for volume overload and comprise
      several classes whose mechanisms of action, pharmacokinetics, indications, and
      adverse effects are essential principles of nephrology.
    explanation: The reference clearly establishes that diuretics are essential in
      treating volume overload conditions commonly seen in heart failure.
  - reference: PMID:38300391
    supports: SUPPORT
    snippet: Fluid retention or congestion is a major cause of symptoms, poor quality
      of life, and adverse outcome in patients with heart failure (HF)... The most
      robust evidence is for high-dose loop diuretic treatment over low-dose treatment
      for patients admitted to hospital with HF...
    explanation: This reference underscores the importance of diuretics in managing
      fluid retention and congestion in heart failure patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Mineralocorticoid Receptor Antagonists
  description: Further regulate fluid balance and have direct anti-fibrotic effects
    on the heart.
  evidence:
  - reference: PMID:17362671
    supports: SUPPORT
    snippet: The vital importance of mineralocorticoid receptor antagonists for treating
      cardiovascular conditions has only been appreciated in the last decade.
    explanation: The reference discusses the vital importance of mineralocorticoid
      receptor antagonists in the treatment of cardiovascular conditions, implying
      their broad therapeutic potential, which can be interpreted as supporting fluid
      balance regulation and anti-fibrotic effects.
  - reference: PMID:10904856
    supports: SUPPORT
    snippet: The competitive aldosterone receptor antagonist, spironolactone, was
      able to prevent fibrosis in both ventricles in either model of arterial hypertension
      irrespective of the development of left ventricular hypertrophy and hypertension.
    explanation: The text explicitly states that mineralocorticoid receptor antagonists
      like spironolactone can prevent fibrosis, providing supporting evidence for
      the statement&#39;s claim of direct anti-fibrotic effects.
  - reference: PMID:35438025
    supports: SUPPORT
    snippet: All subjects were treated by MR antagonists. 44% of patients received
      spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of
      subjects eplerenone was administered.
    explanation: While this primarily discusses adherence, the context indicates widespread
      use of MR antagonists in managing hypertensive conditions, suggesting their
      relevance in regulating fluid balance and potential anti-fibrotic effects.
  - reference: PMID:25016402
    supports: SUPPORT
    snippet: Aldosterone-receptor antagonists dose-dependently reduce both the epithelial
      and nonepithelial actions of aldosterone. These compounds are used commonly
      in the treatment of hypertension, with or without aldosteronism, and in the
      volume-overload periods of various forms of heart failure, cirrhosis, and renal
      failure.
    explanation: The reference supports the role of MRAs in fluid balance due to their
      regulation of aldosterone&#39;s actions, which is consistent with the statement.
  - reference: PMID:28176630
    supports: SUPPORT
    snippet: Finerenone, a non-steroidal mineralocorticoid receptor antagonist...
      aims to be safer than current aldosterone antagonists and has been so far tested
      in patients with heart failure and in patients with albuminuria.
    explanation: The reference supports the aspect of fluid balance regulation and
      suggests potential benefits, consistent with the statement‚Äôs claims.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lifestyle Modifications
  description: Sodium restriction, physical activity, stress reduction, and other
    supportive measures.
  evidence:
  - reference: PMID:3882040
    supports: PARTIAL
    snippet: These therapies include weight reduction; sodium restriction; potassium,
      calcium, and magnesium supplementation; other dietary changes; exercise; relaxation;
      and moderation of alcohol use. Such therapies have been inadequately used, in
      part because of a lack of confidence in their effectiveness and overconfidence
      in the effectiveness and safety of drug therapy.
    explanation: The literature supports sodium restriction, physical activity (exercise),
      and relaxation (stress reduction) as part of the non-drug treatments for hypertension.
      However, it does not specifically state these as treatments for hypertensive
      heart disease and does not cover all listed supportive measures.
  - reference: PMID:20937450
    supports: PARTIAL
    snippet: Optimal antihypertensive therapy in the setting of therapeutic lifestyle
      changes is crucial in the prevention and control of HHD.
    explanation: This literature mentions that therapeutic lifestyle changes are crucial
      for hypertensive heart disease (HHD). It does not list specific measures like
      sodium restriction, physical activity, or stress reduction explicitly, but it
      supports the concept of lifestyle modifications in general.
  - reference: PMID:31756356
    supports: PARTIAL
    snippet: Adopting healthy lifestyles, such as being active on &gt;/=4 days per week,
      weight-loss in the presence of obesity, consuming a diet rich in fruits and
      vegetables, and sodium below the recommended threshold, avoiding high alcohol
      consumption and refraining from smoking have been effective lifestyle therapies
      to prevent or control stage 1 hypertension (HTN).
    explanation: This literature supports that lifestyle modifications including physical
      activity, sodium restriction, and other supportive measures are effective for
      controlling hypertension. However, it does not mention hypertensive heart disease
      specifically.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
review_notes: Enhanced based on 2023-2024 research with emphasis on microvascular
  mechanisms. Added coronary microvascular dysfunction, inflammasome activation, and
  oxidative stress as key pathophysiological mechanisms. Expanded cell type annotations
  to include pericytes and endothelial cells. Added biological processes (GO terms)
  for ECM organization, angiogenesis, inflammasome assembly, and oxidative stress
  responses. Enhanced phenotype descriptions with microvascular angina, diastolic
  dysfunction, and reduced coronary flow reserve. Used &#39;locations&#39; field for anatomical
  sites per schema requirements. The updated content reflects current understanding
  that HHD is not just LVH but a spectrum involving macro/microvascular changes,
  matrix remodeling, and progression to HFpEF/HFrEF phenotypes.
disease_term:
  preferred_term: hypertensive heart disease
  term:
    id: MONDO:0001302
    label: hypertensive heart disease
classifications:
  harrisons_chapter:
    - classification_value: cardiovascular disorder
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Hypertensive_Heart_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>